| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | GPAT; PRAT; ATASE |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PPAT |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与PPAT抗体相关的文献示例(内容为虚拟概括，仅供参考)：
1. **文献名称**：PPAT Antibody-Based Detection of Enzyme Overexpression in Triple-Negative Breast Cancer
**作者**：Chen et al. (2022)
**摘要**：本研究利用特异性PPAT单克隆抗体，通过免疫组化技术检测了PPAT在三阴性乳腺癌组织中的表达水平，发现其高表达与患者预后不良相关，提示PPAT可能作为潜在治疗靶点。
2. **文献名称**：Development of a Novel PPAT Polyclonal Antibody for Metabolic Profiling in Hepatocellular Carcinoma
**作者**：Wang et al. (2021)
**摘要**：报道了一种新型兔源PPAT多克隆抗体的开发及验证，通过Western blot和免疫荧光证实其在肝癌细胞系中特异性识别PPAT蛋白，并揭示PPAT表达与肝癌细胞嘌呤代谢异常的相关性。
3. **文献名称**：Targeting PPAT with Neutralizing Antibodies Suppresses Ovarian Cancer Progression in Vivo
**作者**：Kim et al. (2020)
**摘要**：研究团队筛选出靶向PPAT催化结构域的人源化单抗，在卵巢癌小鼠模型中验证其可通过抑制嘌呤合成通路显著减缓肿瘤生长，为抗体疗法提供新思路。
注：以上文献信息为模拟生成，实际引用需查询PubMed、Web of Science等数据库获取真实文献。
PPAT (Phosphoribosyl Pyrophosphate Amidotransferase) is a rate-limiting enzyme in the *de novo* purine biosynthesis pathway, catalyzing the first committed step of converting phosphoribosyl pyrophosphate (PRPP) into phosphoribosylamine. This enzyme plays a critical role in nucleotide metabolism, making it essential for cellular proliferation, DNA/RNA synthesis, and energy homeostasis. Dysregulation of PPAT has been linked to various pathologies, including cancer, where rapidly dividing cells rely heavily on upregulated purine synthesis. Its overexpression in tumors, such as glioblastoma and leukemia, highlights its potential as a therapeutic target.
PPAT antibodies are tools developed to detect, quantify, or inhibit PPAT protein expression in research and diagnostic contexts. These antibodies enable studies on PPAT’s spatial-temporal expression, interaction partners, and regulatory mechanisms. In drug discovery, PPAT inhibitors (e.g., antifolates) are explored for chemotherapy, and antibodies aid in validating target engagement or monitoring therapeutic efficacy. Additionally, PPAT antibodies contribute to understanding metabolic disorders tied to purine imbalance, such as Lesch-Nyhan syndrome. Most PPAT antibodies are raised against conserved epitopes in human or murine PPAT, with applications in Western blotting, immunohistochemistry, and ELISA. Challenges include ensuring specificity due to structural similarities with other amidotransferases. Ongoing research focuses on optimizing antibody performance for precision in complex biological samples.
×
